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SPECIFIC AIMS
Mitochondrial complex I dysfunction has been associ-
ated with neurodegenerative disorders such as Parkin-
son’s disease. As complex I is known to have essential
thiol groups in its subunits, we examined the role of
glutaredoxin, a thiol disulfide oxidoreductase (also
known as thioltransferase), in maintaining the func-
tional integrity of mitochondrial complex I in the
brain under normal conditions and following adminis-
tration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a neurotoxin that produces Parkinson’s dis-
ease-like symptoms in primates, including humans
through inhibition of complex I.
PRINCIPAL FINDINGS
1. Down-regulation of glutaredoxin expression leads
to inhibition of mitochondrial complex I activity
Glutaredoxin was down-regulated selectively in the
brain of Swiss albino mice by injecting phosphorothio-
nate end-capped sense and antisense oligonucleotides
to glutaredoxin (400 g in 2 divided doses at a 12-h
interval), intrathecally. Selective down-regulation of
glutaredoxin in the frontal cortex and striatum resulted
in significant loss of complex I activity in the frontal
cortex and striatum as compared with corresponding
controls (P0.005), and animals treated with vehicle or
sense nucleotides were unaffected (Fig. 1a, b, and Fig.
2). In the hippocampus, glutaredoxin was not down-
regulated, and complex I activity was similar to vehicle-
treated controls (Fig. 2). These results reveal the im-
portant role of glutaredoxin in maintaining functional
integrity of mitochondrial complex I in brain regions
under normal conditions.
2. Mitochondrial complex I inhibition caused by
down-regulation of glutaredoxin expression is a result
of impaired thiol status of the enzyme
Complex I activity was measured after incubating mito-
chondria from antisense oligonucleotide-treated ani-
mals with the thiol reductant DTT; this completely
restored complex I activity to the levels similar to
corresponding controls (Fig. 1c), indicating that the
oxidation of critical thiol groups in the enzyme com-
plex was responsible for the loss of enzyme activity
caused by down-regulation of glutaredoxin.
3. Up-regulation of glutaredoxin is essential for
recovery of mitochondrial complex I function from
toxic insult caused by MPTP administration
We examined the relationship between the functional
status of glutaredoxin and complex I in the striatum of
mice following a single, systemic dose of MPTP (30
mg/kg body weight, s.c.). Complex I activity was signif-
icantly decreased at 0.5 h after MPTP administration.
However, after 4 h, complex I activity recovered and
was significantly higher than corresponding controls
(121% of controls; P0.002). During the recovery of
complex I activity in the striatum glutaredoxin, activity
increased significantly to 190% of the corresponding
controls (P0.002). However, glutaredoxin activity was
similar to controls 18 h after MPTP administration, and
simultaneously, loss in complex I activity was observed.
Thus, a direct correlation was seen between the func-
tional status of complex I and glutaredoxin activity.
4. Glutaredoxin protein expression increased in the
striatum following a single dose of MPTP
administration
To examine whether the increase in glutaredoxin ac-
tivity in the striatum was a result of increased expres-
sion of glutaredoxin protein, immunoblot and immu-
nohistochemical analyses were performed using antibody
to human red blood cell glutaredoxin, which shares
100% homology with the brain glutaredoxin. Immuno-
blot analysis showed a significant increase in glutare-
doxin protein expression 4 h after MPTP administra-
tion in the striatum compared with corresponding
controls (P0.05). In the hippocampus, a brain region
unaffected by MPTP, no change was observed in the
expression levels of glutaredoxin. Immunohistochemi-
cal analysis revealed increased expression of glutare-
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doxin protein in striatal neurons of MPTP-treated
animals compared with vehicle-treated animals.
5. Glutaredoxin mRNA expression increased in the
striatum following MPTP administration
Total RNA was extracted from the striatum of control
and MPTP-treated mice, and Northern blot analysis was
preformed using cDNA to glutaredoxin. We observed
an increased level of glutaredoxin mRNA 1 h after
MPTP administration in the striatum compared with
vehicle-treated animals. In situ hybridization studies
also revealed increased transcription of glutaredoxin
mRNA in striatal neurons of MPTP-treated animals
compared with vehicle-treated animals.
6. Redox-sensitive transcription factors, activated
protein 1 (AP1), antioxidant response element (ARE),
and nuclear factor (NF)[]B, are activated in the
striatum following a single dose of MPTP
administration
Nuclear extracts were prepared from the striatum of
vehicle, and MPTP-treated mice, electrophoretic mobility
shift assays (EMSAs), and supershift assays were per-
formed using the nuclear extracts and 32P-labeled oligo-
nucleotides containing consensus-binding sequences for
AP1, ARE, or NF[]B. EMSA revealed significantly in-
creased binding of AP1, ARE, and NF[]B within 30 min
of MPTP administration compared with corresponding
Figure 1. Disulfide reductant dithiothreitol (DTT) restores
mitochondrial complex I activity lost by down-regulation of
glutaredoxin. Mice were administered sense or antisense
(AS) oligonucleotides to glutaredoxin in two divided doses
(200 g/dose, intrathecally) at 12-h intervals, the animals
were killed 12 h after the last injection, and the striatum
was dissected out. Control (CON) animals received vehicle
alone. a) Glutaredoxin activity was measured in the stria-
tum. Complex I activity was measured in the mitochondria
of the striatum in the absence (b) and presence (c) of DTT.
Complex I activity is expressed as nmole of reduced
nicotinamide adenine dinucleotide (NADH) oxidized/
min/mg of protein, and glutaredoxin activity is expressed
as nmole of NADH phosphate (NADPH) oxidized/
min/mg of protein. Values are mean  sd (n3 animals).
*, Values are significantly different from control animals
(P0.001).
Figure 2. Effect of down-regulation of glutaredoxin expres-
sion on MPTP-mediated mitochondrial complex I activity.
Mice were administered sense or antisense oligonucleotides
to glutaredoxin in two divided doses (200 g/dose, intrathe-
cally) at 12-h intervals. MPTP [30 mg/kg body weight, subcu-
taneously (s.c.)] was injected 8 h after the second injection of
oligonucleotides. Animals were killed 4 h after MPTP admin-
istration. Another group of animals were administered MPTP
alone and were killed 4 h later. Control animals received
vehicle alone. Glutaredoxin and complex I activities were
measured in the frontal cortex (FCT), hippocampus (HP),
and striatum (ST). Complex I and glutaredoxin activities are
expressed as nmoles of NADH oxidized/min/mg of protein
and nmoles of NADPH oxidized/min/mg of protein, respec-
tively. Values are mean  sd (n3 animals). *, Values signifi-
cantly different from vehicle-treated controls (P0.001).
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controls (P0.005). The activation of AP1 was super-
shifted by antibody to p-c-Jun, JunB, and c-Fos, indicating
the possible involvement of these proteins in the activa-
tion of the AP1 complex.
Thus, 30 min after MPTP administration, we observed
activation of the AP1 transcription factor followed by
increased transcription of glutaredoxin mRNA at 1 h
Increased expression of glutaredoxin protein and activity
was seen at 4 h, which in turn mediated recovery of
complex I function caused by MPTP administration.
7. Glutaredoxin is critical during recovery of
mitochondrial complex I function from toxic insult
caused by MPTP administration
The role of glutaredoxin in mediating recovery of
complex I function following MPTP administration (30
mg/kg body weight, s.c.) was further confirmed by
administration of MPTP to mice pretreated with anti-
sense oligonucleotides to glutaredoxin. Antisense oli-
gonucleotides were administered intrathecally to mice
at a dose of 200 g twice at a 12-h interval. MPTP was
administered 8 h after the second injection of the
oligonucleotides. The frontal cortex, hippocampus,
and striatum were dissected out, and glutaredoxin and
complex I activities were assayed. Antisense oligonucle-
otides completely abolished the recovery of complex I
in the striatum, which would otherwise have occurred
4 h after MPTP administration, demonstrating the
critical role played by glutaredoxin in restoring com-
plex I function (Fig. 2).
CONCLUSION AND SIGNIFICANCE
Complex I is known to possess active thiol groups and is
extremely sensitive to the thiol status in cells. Depletion of
reduced glutathione (GSH) in PC12 cells through down-
regulation of -glutamyl cysteine synthetase (the rate-
limiting enzyme in GSH synthesis) leads to selective
inhibition of complex I. However, the factors involved in
maintenance of complex I under normal conditions and
during recovery from oxidative stress are not well defined.
This study demonstrates the critical role of glutare-
doxin in maintaining the functional integrity of brain
mitochondrial complex I under normal conditions and
during recovery from oxidative stress such as that
mediated by MPTP, a neurotoxin that causes Parkin-
son’s disease. Complex I dysfunction has been noted in
post-mortem brain samples and peripheral tissues from
Parkinson’s disease patients; however, the mechanisms
underlying this dysfunction remain unclear (Fig. 3).
Loss of GSH is also seen in the substantia nigra of
patients with Parkinson’s disease. Inhibition of glutathi-
one synthesis has been shown to selectively result in
complex I loss in PC12 cell lines.
Glutaredoxin, a thiol disulfide oxidoreductase dis-
covered 25 years ago, reduces protein glutathione-
mixed disulfides to protein thiols using reducing equiv-
alents of GSH. Although the potential role of
glutaredoxin in protection against oxidative injury has
been hypothesized, its regulation during oxidative
stress has not been clearly defined through experimen-
tal evidence. The present study provides evidence of
differential regulation of glutaredoxin at the transcrip-
tional level during recovery of mitochondria from
oxidative stress and also provides evidence for its role in
maintaining functionality of mitochondrial complex I
in normal conditions. This is of significance, as main-
tenance of reduced thiol status of mitochondrial com-
plex I is important not only for proper mitochondrial
function but also in the management of neurodegen-
erative diseases, such as Parkinson’s disease, which are
associated with complex I dysfunction.
This study provides irrevocable evidence for the role
of glutaredoxin in maintaining complex I function and
thus ensuring mitochondrial integrity. Further, glutare-
doxin plays a critical role in the recovery of complex I
impaired by oxidative stress caused by neurotoxins such
as MPTP.
Figure 3. Schematic illustration depicting
the important role of glutaredoxin (a
thiol disulfide oxido-reductase) in main-
taining functional integrity of mitochon-
drial complex I under normal conditions
and during oxidative stress caused by gen-
eration of reactive oxygen species (ROS).
Reduced protein thiol status is essential
for complex I function and down-regula-
tion of glutaredoxin is associated with loss
of complex I activity. Oxidative stress
which could lead to protein thiol oxida-
tion and complex I dysfunction has been
associated with Parkinson’s disease.
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